Wall Street analysts predict that Kezar Life Sciences Inc (NASDAQ:KZR) will post earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.35). The business is expected to report its next quarterly earnings results on Thursday, March 28th.
According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($2.37) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($2.37) per share, with EPS estimates ranging from ($2.84) to ($1.90). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Kezar Life Sciences.
Several analysts have recently issued reports on KZR shares. Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Tuesday, November 27th. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th. Finally, ValuEngine lowered shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Kezar Life Sciences presently has a consensus rating of “Buy” and an average target price of $24.33.
Several hedge funds and other institutional investors have recently bought and sold shares of KZR. New York State Common Retirement Fund bought a new position in shares of Kezar Life Sciences in the 4th quarter worth approximately $73,000. BlackRock Inc. grew its stake in shares of Kezar Life Sciences by 1.9% during the fourth quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares during the last quarter. Northern Trust Corp boosted its position in Kezar Life Sciences by 8.7% in the fourth quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock valued at $1,345,000 after buying an additional 4,581 shares during the last quarter. Slow Capital Inc. purchased a new stake in Kezar Life Sciences in the fourth quarter valued at approximately $216,000. Finally, Prosight Management LP boosted its position in Kezar Life Sciences by 25.5% in the third quarter. Prosight Management LP now owns 52,331 shares of the company’s stock valued at $1,120,000 after buying an additional 10,640 shares during the last quarter. 48.89% of the stock is currently owned by institutional investors.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
See Also: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.